Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy

Nathaniel Lizak, Suzanne Hodgkinson, Ernest Butler, Jeannette Lechner-Scott, Mark Slee, Pamela Ann McCombe, Cameron Shaw, Olga Skibina, Steve Vucic, Neil Shuey, Michael H. Barnett, John Parratt, Helmut Butzkueven, Dominic Jack, Jessica Fabris, Tomas Kalincik

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

Background/objective: Observational clinical data from cladribine-treated patients with relapsing forms of multiple sclerosis (MS) were recorded in the Australian MS registry powered by the MSBase registry platform (5-year follow-up) and analysed to complement information from the pivotal cladribine clinical trials in MS. Methods: A cohort of 90 cladribine-treated patients with follow-up data reported by treating physicians and recorded in the Australian MSBase registry (database lock February 2016) were examined. Clinical data included Expanded Disability Status Scale (EDSS) scores, relapses and other disease-modifying drugs (DMDs) administered before and after cladribine treatment. Results: Mean age on starting cladribine was 47 years; mean age at MS onset was 34 years, and median baseline EDSS score was 5.25. Disability trajectories in patients with sufficient follow-up suggested an overall increasing trend prior to cladribine treatment which was reduced during the 2-year post-treatment. Approximately 80% of patients were EDSS progression-free, 65% remained relapse-free after 2 years and median time to next DMD was 1.7 years. Conclusion: These observational data suggest a disease-modifying effect in this cohort of relapsing MS patients characterised by older and more disabled patients. Since these data represent a single-arm cohort, clinical trials and larger comparative post-marketing studies are needed to validate and extend these findings.

Original languageEnglish
Number of pages10
JournalMultiple Sclerosis Journal
Early online date12 Jun 2020
DOIs
Publication statusE-pub ahead of print - 12 Jun 2020

Bibliographical note

https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Keywords

  • Cladribine tablets
  • disease-modifying drug
  • MSBase registry
  • multiple sclerosis
  • observational
  • real world

Fingerprint Dive into the research topics of 'Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy'. Together they form a unique fingerprint.

Cite this